Compare TIMB & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIMB | PODD |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 10.3B |
| IPO Year | 2020 | 2007 |
| Metric | TIMB | PODD |
|---|---|---|
| Price | $21.83 | $148.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 21 |
| Target Price | $25.10 | ★ $341.48 |
| AVG Volume (30 Days) | 364.7K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.30 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $8.47 | $24.55 |
| Revenue Next Year | $4.80 | $19.18 |
| P/E Ratio | ★ $15.81 | $110.09 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $17.18 | $140.63 |
| 52 Week High | $28.22 | $354.88 |
| Indicator | TIMB | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 33.34 | 36.83 |
| Support Level | $21.69 | $145.59 |
| Resistance Level | $22.47 | $205.95 |
| Average True Range (ATR) | 0.39 | 6.24 |
| MACD | 0.01 | 1.11 |
| Stochastic Oscillator | 10.40 | 41.72 |
TIM, which is 67%-owned by Telecom Italia, is the third-largest wireless carrier in Brazil, with 62 million subscribers, equal to about 23% of the market. The firm owns 49% of I-Systems, an infrastructure partnership that is expanding its network footprint across Brazil. I-Systems can provide broadband service to about 8 million locations, including 6.5 million with fiber, equal to 10%-15% of the country. TIM leases capacity on the venture's network to serve retail broadband customers under the UltraFibra brand, but it has agreed to buy out its joint venture partner in 2026 and will take full ownership of these assets. TIM also resells fiber network access from other providers.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.